CooperVision® Introduces Next Generation Myopia Control Soft Contact LensMyDay® MiSight® 1 day
The brand is strengthening its commitment to paediatric eyecare by combining its clinically proven ActivControl® Technology in a new silicone hydrogel myopia control lens.*1
SYDNEY, AUSTRALIA, 23 FEBRUARY 2026 - CooperVision, a global leader in myopia management, announced the launch of its new myopia control soft contact lens, MyDay® MiSight® 1 day, that combines the proven ActivControl® Technology of MiSight® 1 day with the advanced silicone hydrogel material used in MyDay® lenses.*1 The lens will be available for wearers in Australia and New Zealand from 2 March 2026.
The introduction of MyDay® MiSight® 1 day builds on the success of MySight® 1 day, the number one fitted soft contact lens brand for myopia control, worn by over 200,000 children worldwide.†2,3 The lens provides the same clear vision and myopia control benefits of the world renowned MiSight® 1 day design, with excellent comfort, enhanced ease of handling and breathability over the original MiSight® 1 day.‡§◊4,5 Wearers of the new lens will also benefit from a built-in UV inhibitor to help protect the cornea and crystalline lens against transmission of harmful UV radiation.¶
Myopia – A Growing Challenge
By 2050, myopia is projected to affect half the world’s population. The increasing prevalence of myopia and corresponding clinical and societal impacts necessitate a coordinated global response.6
“CooperVision has spent over a decade building expertise in myopia management across more than 40 countries,” said Michelle North, General Manager CooperVision Australia & New Zealand. “MyDay® MiSight® 1 day brings together our most advanced contact lens material with an optical design already trusted by hundreds of thousands of parents and children worldwide.*1* “Myopia is irreversible and typically progresses rapidly in younger children.7 Wearing time is critical for effective myopia control, yet children do not consistently wear their spectacles.**8”
Contact lenses make it easy for children to achieve the maximum wearing time for myopia control. † †4,9,10 In a clinical trial, featuring ActivControl® Technology, requiring children to wear contact lenses at least 10 hours per day 6 days per week, children wore their lenses for 13- 14 hours per day and more than 6.5 days per week.‡‡9 “MyDay® MiSight® 1 day contact lenses offer ‘always-on’ myopia control, making it easy for children to achieve maximum myopia control wearing time because children wear them all day,” §§4,9 said Michelle North.
ActivControl® Technology used in both MiSight® 1 day and MyDay® MiSight® 1 day has been shown through clinical studies and research spanning 10 years, to slow myopia progression similar to levels seen in emmetropic eyes when worn as prescribed.◊◊5,11 Importantly, the myopia control benefits from ActivControl® Technology in MyDay® MiSight® 1 day were retained after treatment ended.¶¶12
The silicone hydrogel material in the new MyDay® MiSight® 1 day lens provides up to 4 times the oxygen transmissibility compared with traditional hydrogel lenses and supports sustained comfort throughout the day.◊13
In clinical evaluations involving children, MyDay® MiSight® 1 day demonstrated high levels of wearability, including 100% fitting success, excellent handleability and visual acuity measuring better than 6/6.***,†††,‡‡‡,4
Philip Cheng, an optometrist whose practice in Melbourne specialises in myopia management commented, “Having the ActivControl® Technology of MiSight® 1 day available in a silicone hydrogel material is a welcome development that will benefit many patients.”
Supporting Long Term Vision Pathways
The introduction of MyDay® MiSight® 1 day further strengthens CooperVision’s evidence-based myopia management portfolio.
MyDay® MiSight® 1 day only differs from MyDay® sphere by virtue of its optical design. Patients no longer requiring myopia management can therefore easily transition to single-vision correction contact lenses from the same family once their myopia progression has stabilised, without any need for adaptation or refitting.§§§
MEDIA CONTACT
Jacqui May, CooperVision ANZ
Mobile: +61 0459 395 527
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
References:
*Proven to slow myopia progression in children compared to a single vision 1-day lens over a 3-year period.
†Based on available fit data in the UK and US for patients under 20
‡Mean score for subjective overall comfort was 90/100 after 1 week of daily wear
§ 94% vs. 81% after 1 week of daily wear, p=NS.
◊Based on manufacturers published data. MyDay® MiSight® 1 day has Dk/t of 100. Compared to the original MiSight 1 day (Dk/t28), NaturalVue Multifocal 1 Day (Dk/t 25)
¶ Warning: UV-absorbing contact lenses are not substitutes for protective UV-absorbing eyewear, such as UV-absorbing goggles or sunglasses, because they do not completely cover the eye and surrounding area. Patients should continue to use UV-absorbing eyewear as directed
**Compliance with spectacle use in children is highly variable; broken spectacles, loss, forgetfulness, parental and children's perceptions, peer pressure, and the patient's self-esteem are a few reasons cited for poor compliance.
†† Studies conducted with MiSight® 1 day and MyDay® MiSight® 1 day.
‡‡ Mean weekday wear time increased from 12.8 hours/day at 6-months to 13.9 hours/day at 6-years with a mean of >6.5 days/week.
§§ In a clinical study, mean weekday wearing time increased from 12.8 hours/day at 6 months to 13.9 hours/day at 6 years with a mean of >6.5 days/week for MiSight® 1 day, which shares the same ActivControl® Technology with MyDay® MiSight® 1 day.
◊◊ MyDay® MiSight® 1 day contact lenses use the same ActivControl® Technology as the original MiSight® 1 day. In clinical study, the average 3-year elongation in myopes treated with contact lenses with ActivControl® Technology approached that of virtual cohorts of emmetropes with the same age distribution.
¶¶ 12 months post-treatment, evidence indicates that no accumulated myopia control benefits were lost following 3 or 6 years of treatment with MiSight® 1 day (on average, for children aged 8-15 at start of wear), which shares the same ActivControl® Technology with MyDay® MiSight® 1 day. Instead, eye growth reverted to expected, age average myopic progression rates.
*** 100% fit acceptance with mean scores for fit acceptance (3.4/4).
††† After 1 week of daily wear, 41% rated Excellent (no problems with lens application and removal), 34% rated Very good (occasional difficulty with application and removal), 22% rated Good (some problems with application and removal but usually successful).
‡‡‡ VA (LogMAR) > 6/6 for both study visits (dispense and 1 week).
§§§ MyDay® daily disposable
